Integrated systems modeling of severe asthma: Exploration of IL‐33/ST2 antagonism
Open Access
- 20 July 2022
- journal article
- research article
- Published by Wiley in CPT: Pharmacometrics & Systems Pharmacology
- Vol. 11 (9) , 1268-1277
Abstract
Asthma is a complex, heterogeneous disease with a high unmet medical need, despite therapies targeting a multitude of pathways. The ability to quantitatively integrate preclinical and clinical data on these pathways could aid in the development and testing of novel targets and therapeutics. In this work, we develop a computational model of asthma biology, including key cell types and mediators, and create a virtual population capturing clinical heterogeneity. The simulated responses to therapies targeting IL-13, IL-4R alpha, IL-5, IgE, and TSLP demonstrate agreement with clinical endpoints and biomarkers of type 2 (T2) inflammation, including blood eosinophils, FEV1, IgE, and FeNO. We use the model to explore the potential benefit of targeting the IL-33 pathway with anti-IL-33 and anti-ST2. Model predictions are compared with data on blood eosinophils, FeNO, and FEV1 from recent anti-IL-33 and anti-ST2 trials and used to interpret trial results based on pathway biology and pharmacology. Results of sensitivity analyses on the contributions of IL-33 to the predicted biomarker changes suggest that anti-ST2 therapy reduces circulating blood eosinophil levels primarily through its impact on eosinophil progenitor maturation and IL-5-dependent survival, and induces changes in FeNO and FEV1 through its effect on immune cells involved in T2 cytokine production. Finally, we also investigate the impact of ST2 genetics on the conferred benefit of anti-ST2. The model includes representation of a wide array of biologic mechanisms and interventions that will provide mechanistic insight and support clinical program design for a wide range of novel therapies during drug development.Keywords
This publication has 30 references indexed in Scilit:
- Functional analysis of protective IL1RL1 variants associated with asthma riskJournal of Allergy and Clinical Immunology, 2015
- Decoding asthma: Translating genetic variation in IL33 and IL1RL1 into disease pathophysiologyJournal of Allergy and Clinical Immunology, 2013
- Regulation of leukotriene and 5oxoETE synthesis and the effect of 5-lipoxygenase inhibitors: a mathematical modeling approachBMC Systems Biology, 2012
- Measurement of IL-13–Induced iNOS-Derived Gas Phase Nitric Oxide in Human Bronchial Epithelial CellsAmerican Journal of Respiratory Cell and Molecular Biology, 2007
- Eosinophils and asthmaCurrent Allergy and Asthma Reports, 2007
- The role of eosinophils in the pathogenesis of asthmaTrends in Molecular Medicine, 2005
- The Roles of Cells and Mediators in a Computer Model of Chronic AsthmaInternational Archives of Allergy and Immunology, 2001
- Asthma: From Bronchoconstriction to Airways Inflammation and RemodelingAmerican Journal of Respiratory and Critical Care Medicine, 2000
- Molecular basis for selective eosinophil trafficking in asthma: A multistep paradigm☆☆☆Journal of Allergy and Clinical Immunology, 1999
- Characterization of inducible nitric oxide synthase expression in human airway epithelium.Environmental Health Perspectives, 1998